Summit Therapeutics plc Stock

An analyst's downbeat new take on Summit Therapeutics (NASDAQ: SMMT) pushed its stock downward on Hump Day. At the end of Wednesday, the shares had booked a loss of over 11% in price as investors

Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after

Shares of Summit Therapeutics (NASDAQ: SMMT) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an

Shares of Summit Therapeutics (NASDAQ: SMMT) have plunged 31% as of 1:23 p.m. ET Friday, following the release of some trial data this morning.

Summit has been a tremendous winner over the past

Many investors love the "big mo." That's short for "big momentum." Stocks that are on a roll often keep the good times going.

Three Fool.com contributors think they've found high-flying biotech

Summit Therapeutics (NASDAQ: SMMT) has more than just a potential blockbuster cancer drug in its portfolio. Ivonescimab could be one of the best drugs to ever hit the market. This has investors

It's hard to find a biotech company that has performed better than Summit Therapeutics (NASDAQ: SMMT) in the past year. The stock is up by a whopping 512%, and it's no secret why.

Summit, a

Billionaire Ken Griffin is a major supporter of President Donald Trump and donated $100 million last year to conservative groups. However, Griffin isn't a fan of all the president's policies.

He

Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the place on Friday. Both U.S.-based Summit Therapeutics (NASDAQ: SMMT) and

Shares of lung cancer biotech Summit Therapeutics (NASDAQ: SMMT) rocketed 14.7% on Wednesday as of 1:45 p.m. ET.

The markets were broadly up today on a potential easing of trade tensions with China

Nobody has more information about a company than its insiders, especially its executive management team. That's why when one of them buys more shares, it sometimes gives individual investors

Aswath Damodaran teaches corporate finance and valuation at the Stern School of Business at New York University. In this podcast, Motley Fool Senior Analyst Matt Argersinger caught up with Damodaran

Shares of lung cancer-focused biotech Summit Therapeutics (NASDAQ: SMMT) rallied 16.6% at its highs of the day before settling into a 10.4% gain on Thursday as of 3:54 p.m. EDT, even though the

Equity markets recently dipped due to concerns of deteriorating macroeconomic conditions, with the latest trigger being President Trump's trade wars. The S&P 500 index's performance over the

Is the excitement surrounding chipmaker Nvidia fading? As of Monday, shares of the tech giant were down 19% since the start of 2025. Whether that's due to its high valuation, concerns about the

Shares of biotechnology stocks such as Recursion Pharmaceuticals (NASDAQ: RXRX), Summit Therapeutics (NASDAQ: SMMT), and CRISPR Therapeutics AG (NASDAQ: CRSP) plunged on Monday, down 9.4%, 5.6%, and

Summit Therapeutics (NASDAQ: SMMT) stock did better than a lot of other equities during an otherwise forgettable trading session on Wednesday. In contrast to other titles that fell notably, Summit

Multiple paths to immense wealth exist. A few lucky people win the lottery. Some start successful businesses. Others invest in stocks that deliver explosive gains.

Summit Therapeutics (NASDAQ: SMMT)

Last year, Summit Therapeutics (NASDAQ: SMMT) was one of the stars of the biotech industry. The company's shares soared following a significant clinical win. Summit's market capitalization of $15.3

The new year started off with considerable fanfare for the cryptocurrency market. Under President Donald Trump's crypto plan, America was going to become "the crypto capital of the world." That

A very bullish analyst move was the news generally responsible for Summit Therapeutics' (NASDAQ: SMMT) healthy mid-week stock price pop. That upward lift was largely holding as of Friday before

Summit Therapeutics (NASDAQ: SMMT) has been one of the hottest stocks to own over the past 12 months, with its valuation soaring 300% during that stretch. But things have slowed of late and since

If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.

Three

Shares of BigBear.ai Holdings (NYSE: BBAI) are flying higher on Wednesday. The company's stock gained 11.6% as of 12:35 p.m. ET, but was up as much as 15.5% earlier in the day. The gain comes as the